

ASX Release

Anatara 4C and updated cash balance

BRISBANE, 30th July 2018: Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30th June 2018. The Company's cash position at the end of the quarter stood at \$7.6m.

“With the signing of an exclusive global agreement with Zoetis for Detach in May 2018, Anatara achieved a major commercial milestone for its shareholders. We are now working on delivering further shareholder value through the development of our technology platform in human gastrointestinal applications” said Dr Tracie Ramsdale, Anatara's Interim CEO.

“Anatara was excited to unveil development plans for our first human product candidate, the Gastrointestinal Reprogramming Product – or GaRP - as announced on 18th July 2018. GaRP is aimed at restoring and maintaining gut health, and managing symptoms associated with gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome – both of which are major market opportunities.”

The Company remains funded for the next two years, with sufficient funds to execute on the development of GaRP to the point of partnering arrangements.

For more information please contact:

Investor inquiries	Media inquiries
Dr Jay Hetzel, Chairman Anatara Lifesciences +61 (0) 7 3394 8202 jhetzel@anatara.com	Jane Lowe IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au

About Anatara Lifesciences

Anatara Lifesciences (ASX: ANR) develops and aims to partner non-antibiotic, oral products for gastrointestinal diseases in animals and humans where there is significant unmet need and large market opportunity. In May 2018, Anatara granted an exclusive licence to the leading global animal health company, Zoetis Inc., for the worldwide development, manufacturing, distribution and marketing of its lead product Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses. Anatara is now focused on developing its human product pipeline for gastrointestinal health applications. For more information, please visit www.anataralifesciences.com.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Anatara Lifesciences Ltd (ASX: ANR)

ABN

41 145 239 872

Quarter ended ("current quarter")

30 June 2018

Consolidated statement of cash flows	Current quarter A'000	Year to date (12 months) A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for	(165)	(1,068)
(a) research and development	-	-
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	(13)
(d) leased assets	-	-
(e) staff costs	(439)	(1,882)
(f) administration and corporate costs	(506)	(1,782)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	8	250
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	17	1,398
1.8 Other	(19)	(13)
1.9 Net cash from / (used in) operating activities	(1,104)	(3,111)
2. Cash flows from investing activities	-	-
2.1 Payments to acquire:		
(a) property, plant and equipment	(7)	(7)
(b) businesses (see item 10)	-	-

For personal use only

Consolidated statement of cash flows	Current quarter A'000	Year to date (12 months) A'000
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:	-	-
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	(7)	(7)
3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	-	-
4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	8,759	10,767
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(1,104)	(3,111)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(7)	(7)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5 Effect of movement in exchange rates on cash held	-	(1)
4.6 Cash and cash equivalents at end of quarter	7,648	7,648

For personal use only

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	948	859
5.2 Call deposits	6,700	7,900
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	7,648	8,759

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

**Current quarter
\$A'000**

183

-

Item 6.1 Reflects amounts paid to directors including director's fees, salaries, superannuation, bonuses and consulting fees (excluding reimbursements).

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

**Current quarter
\$A'000**

-

-

-

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

-

9. Estimated cash outflows for next quarter (*)	\$A'000
9.1 Research and development	633
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	471
9.6 Administration and corporate costs	232
9.7 Other (provide details if material)	-
9.8 Total estimated cash outflows	1,336

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

For personal use only

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: Trace Ramsdale
(Executive Director)

Date: 30/07/2018

Print name: Trace Ramsdale

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

For personal use only